Did someone sneak off with Pfizer's bucket of gold?; Sarepta unveils more data for promising muscular dystrophy drug;

 @FierceBiotech: Breast cancer vaccine developer bags Teva Pharma, Dx deals to bolster PhIII program. Story | Follow @FierceBiotech

@JohnCFierce: Scientists want more work on apoE as Alzheimer's target (amyloid/tau top suspects) Helps illustrate all the confusion. More | Follow @JohnCFierce

 @RyanMFierce: This Pfizer robbery gives new meaning to a favorite phrase of mine: Pharma gold. Report | Follow @RyanMFierce

> Sarepta Therapeutics ($SRPT) released updated data from its Phase IIb study of an experimental RNA drug called eteplirsen for Duchenne muscular dystrophy, announcing continued benefit from treatment for 62 weeks as measured by the 6-minute walk test. Earlier results from the "Study 202" trial sent Sarepta's stock price soaring. Its share price is up more than 4,000% on the year. Release

> Why is Pfizer ($PFE) missing a bucket of gold bought for $700,000? Police investigate. Story

> Scientists from the Gladstone Institutes have called for reviving efforts to pursue drugs that target misfolded apoE4 proteins in Alzheimer's disease, following the failures of programs focused on beta amyloid drugs. Article

> Newron Pharmaceuticals notched shareholder approval for what had been a controversial plan to buy NeuroNova of Sweden. Item

 @FierceMedDev: NanoString Cancer Dx passes second large-scale test. Article | Follow @FierceMedDev

@MarkHFierce: A $3M Series B round goes to Wright Therapy, which makes lymphedema compression products. Safe, steady investment. Release | Follow @MarkHFierce

 @DamianFierce: Get used to this headline: Startup raises money for renal denervation device. More | Follow @DamianFierce

> Wright Therapy raises $3M Series B for home-use pneumatic compression devices. Item

> FDA wants PMA, not 510(k), for Abiomed's Impella. News

> Cardiosonic seeks $16.1M for renal denervation tech. Story

Pharma News

@FiercePharma: GSK loses class-action ruling on Paxil in Canada. News | Follow @FiercePharma

> Mylan tries snatching Ranbaxy's rights to Novartis blockbuster. Article

> Amarin's fish oil future gets slippery with $100 million in debt. Story

> NICE snubs Pfizer's Inlyta kidney cancer drug. Report


Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.